We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$980M
AUM Growth
+$260M
Cap. Flow
+$316M
Cap. Flow %
32.2%
Top 10 Hldgs %
50.1%
Holding
93
New
25
Increased
16
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$25.5M
2
GLUE icon
Monte Rosa Therapeutics
GLUE
+$18.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.9M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$16.5M
5
IMNM icon
Immunome
IMNM
+$16.1M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$14.2M
2
CGON icon
CG Oncology
CGON
+$11M
3
VRDN icon
Viridian Therapeutics
VRDN
+$10.8M
4
PFE icon
Pfizer
PFE
+$10.4M
5
AVTX icon
Avalo Therapeutics
AVTX
+$9.52M

Sector Composition

Rank Sector Weight
1 Healthcare 85.36%
2 Financials 1.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FULC icon
51
CALL
Fulcrum Therapeutics
FULC
$283M
$3.01M 0.31%
391,900
– –
ABEO icon
52
Abeona Therapeutics
ABEO
$361M
$2.91M 0.3%
648,942
+21,204
+3% +$106K
CAMP icon
53
CAMP4 Therapeutics
CAMP
$282M
$2.88M 0.29%
+653,594
New +$3.1M
ANNX icon
54
Annexon
ANNX
$862M
$2.75M 0.28%
+496,461
New +$2.79M
ELUT icon
55
Elutia
ELUT
$38M
$2.62M 0.27%
2,498,020
-253,294
-9% -$253K
CBIO
56
Crescent Biopharma
CBIO
$618M
$2.4M 0.24%
+130,500
New +$1.5M
MNPR icon
57
Monopar Therapeutics
MNPR
$741M
$2.38M 0.24%
+43,488
New +$2.63M
OVID icon
58
Ovid Therapeutics
OVID
$523M
$2.22M 0.23%
+1,000,000
New +$1.79M
NXTC icon
59
NextCure
NXTC
$37.9M
$1.88M 0.19%
176,057
– –
CMPS
60
Compass Pathways
CMPS
$1.84B
$1.66M 0.17%
+300,000
New +$2.02M
NMRA icon
61
Neumora Therapeutics
NMRA
$321M
$1.6M 0.16%
+818,156
New +$2.12M
SION
62
Sionna Therapeutics
SION
$296M
$1.58M 0.16%
39,417
-2,043
-5% -$78K
TELA icon
63
TELA Bio
TELA
$30.4M
$1.4M 0.14%
2,259,312
-388,200
-15% -$337K
EWTX icon
64
Edgewise Therapeutics
EWTX
$4.69B
$1.34M 0.14%
42,615
+563
+1% +$16.2K
REPL icon
65
Replimune Group
REPL
$1.42B
$1.32M 0.13%
+171,936
New +$1.31M
GENB
66
Generate Biomedicines
GENB
$1.93B
$1.25M 0.13%
+100,000
New +$1.22M
CMPX icon
67
CALL
Compass Therapeutics
CMPX
$407M
$912K 0.09%
+172,400
New +$995K
RADX
68
Radiopharm Theranostics
RADX
$20.9M
$806K 0.08%
187,406
– –
GUTS icon
69
Fractyl Health
GUTS
$105M
$779K 0.08%
1,701,625
-8,138,416
-83% -$7.5M
IBIO icon
70
iBio
IBIO
$69.5M
$429K 0.04%
226,000
+120,000
+113% +$278K
ADGM
71
Adagio Medical Holdings
ADGM
$15.3M
$290K 0.03%
251,972
-263,412
-51% -$267K
AARD
72
Aardvark Therapeutics
AARD
$140M
$127K 0.01%
33,684
-270,255
-89% -$2.8M
RCKTW icon
73
Rocket Pharmaceuticals Warrant
RCKTW
$96.1K
$2.16K ﹤0.01%
104,828
– –
AMLX icon
74
Amylyx Pharmaceuticals
AMLX
$2.5B
– –
-506,242
Closed -$6.12M
AVTX icon
75
Avalo Therapeutics
AVTX
$1.04B
– –
-524,436
Closed -$9.52M
1 2
3
4

Similar funds

MK
MASTERINVEST Kapitalanlage Vienna $962M AUM 27.59% 1-Year Est. Return
QIM
Quantitative Investment Management Charlottesville, Virginia $963M AUM 12.95% 1-Year Est. Return
TC
TwinBeech Capital Purchase, New York $965M AUM 0.23% 1-Year Est. Return
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
PO
Paradigm Operations San Francisco, California $954M AUM 20.29% 1-Year Est. Return

Silverarc Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Silverarc Capital Management held 93 positions worth $980M, up 36% from $720M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management deployed $316M of net new capital in Q1 2026, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Zenas BioPharma: 1,135,935 shares worth $22.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Abivax, an estimated $14.2M trimmed.

  • Silverarc Capital Management's largest Q1 2026 buy was Zenas BioPharma: 1,135,935 shares worth $22.2M.
  • Silverarc Capital Management added most to Monte Rosa Therapeutics in Q1 2026, an estimated $18.6M increase.
  • Silverarc Capital Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $14.2M.
  • Silverarc Capital Management fully exited Viridian Therapeutics in Q1 2026, selling an estimated $10.8M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $980M portfolio in Q1 2026.
  • Silverarc Capital Management opened 25 new positions and closed 20 in Q1 2026.
  • Silverarc Capital Management's portfolio value rose 36% quarter-over-quarter to $980M.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.